title: Contrasting effects of cPLA2 on epithelial Na+ transport.
abstract: Activity of the epithelial Na+ channel (ENaC) is the limiting step for discretionary Na+ reabsorption in the cortical collecting duct. Xenopus laevis kidney A6 cells were used to investigate the effects of cytosolic phospholipase A2 (cPLA2) activity on Na+ transport. Application of aristolochic acid, a cPLA2 inhibitor, to the apical membrane of monolayers produced a decrease in apical [3H]arachidonic acid (AA) release and led to an approximate twofold increase in transepithelial Na+ current. Increased current was abolished by the nonmetabolized AA analog 5,8,11,14-eicosatetraynoic acid (ETYA), suggesting that AA, rather than one of its metabolic products, affected current. In single channel studies, ETYA produced a decrease in ENaC open probability. This suggests that cPLA2 is tonically active in A6 cells and that the end effect of liberated AA at the apical membrane is to reduce Na+ transport via actions on ENaC. In contrast, aristolochic acid applied basolaterally inhibited current, and the effect was not reversed by ETYA. Basolateral application of the cyclooxygenase inhibitor ibuprofen also inhibited current. Both effects were reversed by prostaglandin E2 (PGE2). This suggests that cPLA2 activity and free AA, which is metabolized to PGE2, are necessary to support transport. This study supports the fine-tuning of Na+ transport and reabsorption through the regulation of free AA and AA metabolism.
authors.affiliation: Department of Physiology, Center for Cell and Molecular Signaling, Emory University, Atlanta, Georgia 30322, USA. rworrell@emory.edu
authors.forename: R T
authors.initials: RT
authors.lastname: Worrell
authors.forename: H F
authors.initials: HF
authors.lastname: Bao
authors.forename: D D
authors.initials: DD
authors.lastname: Denson
authors.forename: D C
authors.initials: DC
authors.lastname: Eaton
mesh_terms: D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000818:Animals; D034341:Aristolochic Acids; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000502:physiology; D015232:Dinoprostone / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D053503:Epithelial Sodium Channels; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D017136:Ion Transport; D007668:Kidney / Q000166:cytology; D018408:Patch-Clamp Techniques; D010616:Phenanthrenes / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D054467:Phospholipases A2; D012964:Sodium / Q000378:metabolism*; D015222:Sodium Channels / Q000378:metabolism*; D014982:Xenopus laevis
chemical_list: D034341:Aristolochic Acids; D004791:Enzyme Inhibitors; D053503:Epithelial Sodium Channels; D005231:Fatty Acids, Unsaturated; D010616:Phenanthrenes; D015222:Sodium Channels; D015117:5,8,11,14-Eicosatetraynoic Acid; C059778:7,7-dimethyl-5,8-eicosadienoic acid; C000228:aristolochic acid I; D012964:Sodium; D010741:Phospholipases A; D054467:Phospholipases A2; D015232:Dinoprostone